Monkey pox case: update as of October 18, 2022

In early May 2022, cases of monkey pox (Monkeypox) not directly linked to travel to Central or West Africa where the virus is present, or people returning from travel, were reported in Europe and the world. Since that date, the disease has been the subject, in France and in Europe, of enhanced surveillance based on the Mandatory Declaration, the updated form of which has been presented.

Update in France

As of 18 October 2022 at 12:00 p.m., 4,084 confirmed cases of infection with the Monkeypox virus have been replaced in France, i.e. 20 additional cases since the assessment of October 11.

The distribution of confirmed cases by region of residence (or by reporting region when the region of residence is unknown) is presented in figure 1. The Ile-de-France region concentrates the largest number of cases (2,492, i.e. 61, 0%), followed by Occitania (312 cases), Provence-Alpes-Côte d’Azur (281 cases) and Auvergne-Rhône-Alpes (268 cases); 22 cases reside abroad.

The vast majority of confirmed adult cases called to date are male and 105 cases over the age of 15 (2.6%) are female. The proportion of female cases increased until W36 (from September 5 to 11) when it reached 13.6% (16 cases out of 118) then decreased until W39 (with 7.5% of confirmed cases, i.e. 3 cases out of 40). Since week 39 (from September 26 to October 2), the number of infected women has remained stable (3 cases per week). Ten (0.24%) children under the age of 15 have been reported as confirmed cases since May 2022. Adult confirmed cases have a median age of 36; 25% of adult cases are under 29 years old and 25% are 43 to 81 years old. Of the confirmed cases for which information is available, 91 (2.2%) were hospitalized due to infection with Monkeypox virus; this proportion remains stable over time.

No deaths have been reported to date.

The distribution of cases according to the date of onset of symptoms (when this is known) is presented in Figure 2. The date of onset of symptoms for cases ranges from May 7 to October 05, 2022. , the data of the last weeks are not consolidated. The reports received do not always mention the date of onset of the symptoms. As an alternative to this information, the distribution of cases according to their date of reporting is presented in Figure 3.

These updated data showed that the peak of contaminations took place at the end of June/beginning of July and that the number of confirmed cases has since decreased. These trends are similar to those revealed on the syndromic data of visits to the emergency room for suspicion of Monkeypox (Oscour®). However, we must remain cautious because improving knowledge of the disease can reduce the need for treatment by the best-informed populations. Several other countries, particularly in Europe, are seeing similar trends in the number of new cases reported over the past 3 months.

Figure 1. Laboratory-confirmed cases of monkeypox (n=4,062 cases) by region of residence (or by reporting region when region of residence is unknown), France, May-October 2022 (data as of 10/18/2022 – 12:00 p.m.)

Figure 2. Biologically confirmed cases of monkeypox (n=3,008 cases, number of missing data: 1,076) by week of onset of symptoms, France, May-October 2022 (data as of 10/18/2022 – 12:00 p.m.).

Figure 2. Biologically confirmed cases of monkeypox (n=3,008 cases, number of missing data: 1,076) by week of onset of symptoms, France, May-October 2022 (data as of 10/18/2022 – 12:00 p.m.).

The data for the last few weeks (in light blue) are not fully consolidated.

Figure 3. Biologically confirmed cases of monkeypox (n= 4,084 cases) by reporting week, France, May-October 2022 (data as of 10/18/2022 – 12:00 p.m.).

Figure 3. Biologically confirmed cases of monkeypox (n= 4,084 cases) by reporting week, France, May-October 2022 (data as of 10/18/2022 – 12:00 p.m.).

The data for the last week (in light blue) is not fully consolidated.

Preventive vaccination against monkeypox

Regarding the vaccination distributor, as of October 18, 2022, 170,912 doses of 3rd generation vaccine have been delivered by the Agency to the territories.

As of October 17, 2022, the total number of doses administered is 125,534 (source: Ministry of Health and Prevention).

Since July 11, 2022, in addition to people who have had risky contact with a sick person, people falling within the indications retained by the HAS can make an appointment to be vaccinated throughout France:

  • Men who have sex with men reporting multiple sex partners.
  • Trans people reporting multiple sex partners.
  • Sex workers.
  • Professionals working in places of sexual consumption.

Vaccination can also be transmitted on a case-by-case basis for health professionals who have to take care of sick people.

For more information on vaccination and access to vaccination sites :

Information and prevention actions

Given what has been observed in Europe on the disease, targeted communication was quickly implemented towards MSM people. The sexosafe.fr site, dedicated to the sexuality of MSM people, is regularly updated with a summary of knowledge on the subject and preventive measures. Poster, radio and digital campaigns were compensated in addition to actions in the field. From June 17 to September 30, the digital campaign generated nearly 958,788 clicks on the banners and over 884,071 visits to the Sexosafe site.

All information on vaccination is updated weekly on the page intended for the general public and that intended for healthcare professionals (accessible without a login) of the Vaccination-info-service site.

Prevention actions are continuously adapted to the evolution of the situation and the state of knowledge.

To facilitate access to information for vulnerable people in precarious situations, a pictorial tool, translated into 8 languages, developed with professionals working with these people is available on Santé Publique France.

The MOBCO newsletter n°9 built with actors in the field concerns vaccination. It is aimed at professionals or volunteers in contact with people in precarious situations.

In France, long-term monitoring of monkeypox through the mandatory notification system is reinforced and information and alert messages are sent to healthcare professionals. Exchanges are also continuing with other European countries, the WHO and the ECDC.

Monkeypox info service: a listening device to answer questions about monkeypox

The “Monkeypox info service” telephone line is accessible every day from 8 a.m. to 11 p.m., on the toll-free number 0 801 90 80 69 (free, anonymous and confidential call and services). This system is in charge of accompanying prevention messages and protective measures, of providing information on symptoms, treatments and vaccination, of advising and of directing people to treatment systems.

Since the line opened in mid-July, 8,081 interviews were conducted on Monkeypox info service.

  • 95 interviews were carried out in week 41 (compared to 98 the previous week).
  • The decrease in the number of calls to the Monkeypox info service device continues this week, but more slowly than in previous weeks.
  • The proportion of women strongly calling for the device drops in week 41 (6% vs. 19% in week 40).
  • The themes mentioned during the interviews remain mainly the means of prevention (56%). These are mainly questions about vaccination and its side effects.
  • Note a 15-point increase (28% vs. 13% in week 40) in calls relating to psychological and relational aspects (fear of being contaminated, risk of contaminating those around you, etc.).

See the previous pointsTo displayHide

Leave a Comment